Lupin Reports 16% Profit Growth in Q1 with Revenue Exceeding ₹8,200 Crore

Lupin announced its Q1 FY2027 results, showing a 16% increase in net profit driven by expanding margins and strong operational performance.

The company's consolidated revenue for the quarter surpassed ₹8,200 crore, exceeding market expectations for the pharmaceutical giant.

Lupin's growth was supported by a robust performance in its US business, which remains a primary focus for the company's future revenue strategy.